U.S. markets open in 3 hours 50 minutes

The Zacks Analyst Blog Highlights: Intel and Edwards Lifesciences

Zacks Equity Research

For Immediate Release

Chicago, IL – April 24, 2020 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Intel Corp. INTC and Edwards Lifesciences EW.

Here are highlights from Thursday’s Analyst Blog:

Intel, Edwards Outperform Q1 Earnings Estimates

Intel Corp., a Zacks Rank #3 (Hold)-rated company prior to its Q1 earnings report after Thursday’s closing bell, easily outpaced estimates on both top and bottom lines. Earnings of $1.45 per share was well ahead of both the $1.28 expected and the 89 cents per share reported in the year-ago quarter. Revenues in the quarter reached $19.83 billion, higher than the $18.75 billion in the Zacks consensus.

PC-related businesses brought in $9.8 billion in Q1, higher than the $9.3 billion analysts were looking for. Intel’s Data Center finished the quarter with $7 billion in sales, ahead of the $6.3 billion estimate. The company has clearly shown its strength as a “work from home” stock, which has justified its 19% stock gain in the past month. Intel has not missed a quarterly earnings estimate since Q4 2013.

That said, we appear to be seeing a “sell the news” scenario with regard to Intel stock, as shares are down 5% upon the earnings release. The company also suspended guidance for its full-year earnings and revenues, while the company guided slightly lower for Q2 2020. For more on INTC’s earnings, click here.

Edwards Lifesciences, another Zacks Rank #3 stock, also outperformed expectations after regular trading ended, with $1.51 per share rocketing past the $1.29 expected and +14% year over year. Sales of $1.1 billion surpassed the $1.05 billion analysts were anticipating. Revenues guidance for next quarter provided a range of $700-900 million, where the Zacks consensus estimate of $821.72 million rests easily.

Full-year guidance, however, was lowered from the previous $4.6-5.0 billion to an updated $4.0-4.5 billion. For more on EW’s earnings, click here.

Free Book: Finding #1 Stocks

In this 300-page hardcover, Zacks' Executive VP Kevin Matras reveals almost every stock-picking secret he’s learned from the system that since 1988 has more than doubled the average yearly gain of the S&P 500.

Learn more now >>

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339

support@zacks.com                                   

https://www.zacks.com                                                 

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performancefor information about the performance numbers displayed in this press release.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Intel Corporation (INTC) : Free Stock Analysis Report
 
Edwards Lifesciences Corporation (EW) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research